Protective effect of rosuvastatin treatment by regulating oxidized low-density lipoprotein expression in a rat model of liver fibrosis

Yu,Shuiping; Zhou,Xueling; Hou,Bingzong; Tang,Bo; Li,Jian; Zhang,Baimeng

doi:10.3892/br.2016.722

Protective effect of rosuvastatin treatment by regulating oxidized low-density lipoprotein expression in a rat model of liver fibrosis

Authors:
- Shuiping Yu
- Xueling Zhou
- Bingzong Hou
- Bo Tang
- Jian Li
- Baimeng Zhang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541000, P.R. China, Department of General Surgery, The Fifth Affiliated Hospital of Sun Yat Sen University, Zhuhai, Guangdong 519000, P.R. China
Published online on: July 19, 2016 https://doi.org/10.3892/br.2016.722
Pages: 311-316
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the protective effect of rosuvastatin treatment on the mechanism of oxidized low‑density lipoprotein (Ox‑LDL) in rats with liver fibrosis. In total, 72 male Sprague‑Dawley rats were divided into 3 groups: 24 in the control group (A), 24 in the obstructive jaundice models group (B) and 24 in the rosuvastatin group (C). Each group was further divided into four subgroups for assessment at different time-points. The obstructive jaundice models were established and rosuvastatin was administered by gavage. Liver fibrosis indicators, Ox‑LDL, malonaldehyde (MDA) and superoxide dismutase (SOD), were measured and liver pathological changes were observed at weeks 1, 2, 3 and 4 after model induction. In groups B and C, the rat models were successfully established, and there were significant changes in the expression of Ox‑LDL and the three liver fibrosis indicators when compared to group A (P<0.01). However, the expression of Ox‑LDL and the three liver fibrosis indicators in group C were decreased compared with group B (P<0.05), while SOD increased (P<0.05) and MDA decreased (P<0.05). The three liver fibrosis indicators were different in comparison to group B (P<0.05). Thus, there appeared to be an association between the expression of Ox‑LDL and liver fibrosis. Treatment with rosuvastatin could regulate the expression of Ox‑LDL and improve liver fibrosis in rat models with obstructive jaundice.

View Figures

View References

1	Yue HY, Yin C, Hou JL, Zeng X, Chen YX, Zhong W, Hu PF, Deng X, Tan YX, Zhang JP, et al: Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut. 59:236–246. 2010. View Article : Google Scholar : PubMed/NCBI
2	Xue ZF, Wu XM and Liu M: Hepatic regeneration and the epithelial to mesenchymal transition. World J Gastroenterol. 19:1380–1386. 2013. View Article : Google Scholar : PubMed/NCBI
3	Neuparth MJ, Proença JB, Santos-Silva A and Coimbra S: Adipokines, oxidized low-density lipoprotein, and C-reactive protein levels in lean, overweight, and obese portuguese patients with type 2 diabetes. ISRN Obes. 2013:1420972013.PubMed/NCBI
4	Karadeniz G, Acikgoz S, Tekin IO, Tascýlar O, Gun BD and Cömert M: Oxidized low-density-lipoprotein accumulation is associated with liver fibrosis in experimental cholestasis. Clinics (Sao Paulo). 63:531–540. 2008. View Article : Google Scholar : PubMed/NCBI
5	Li J, Fan R, Zhao S, Liu L, Guo S, Wu N, Zhang W and Chen P: Reactive oxygen species released from hypoxic hepatocytes regulates MMP-2 expression in hepatic stellate cells. Int J Mol Sci. 12:2434–2447. 2011. View Article : Google Scholar : PubMed/NCBI
6	Bai YP, Hu CP, Chen MF, Xu KP, Tan GS, Shi RZ, Li YJ and Zhang GG: Inhibitory effect of reinioside C on monocyte-endothelial cell adhesion induced by oxidized low-density lipoprotein via inhibiting NADPH oxidase/ROS/NF-kappaB pathway. Naunyn Schmiedebergs Arch Pharmacol. 380:399–406. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kose E, An T, Kikkawa A, Matsumoto Y and Hayashi H: Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. Biol Pharm Bull. 37:226–231. 2014. View Article : Google Scholar : PubMed/NCBI
8	Li Y, Wang Q, Zhou J, Xu Q, Chu X, Sun T, Liu X and Cai S: Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I. Eur J Pharmacol. 723:23–28. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ansari JA, Bhandari U, Haque SE and Pillai KK: Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats. Toxicol Mech Methods. 22:67–73. 2012. View Article : Google Scholar : PubMed/NCBI
10	Aktas C, Kanter M, Erboga M, Mete R and Oran M: Melatonin attenuates oxidative stress, liver damage and hepatocyte apoptosis after bile-duct ligation in rats. Toxicol Ind Health. 30:835–844. 2014. View Article : Google Scholar : PubMed/NCBI
11	Ezhilarasan D, Karthikeyan S and Vivekanandan P: Ameliorative effect of silibinin against N-nitrosodimethylamine-induced hepatic fibrosis in rats. Environ Toxicol Pharmacol. 34:1004–1013. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hong HK, Song CY, Kim BC and Lee HS: ERK contributes to the effects of Smad signaling on oxidized LDL-induced PAI-1 expression in human mesangial cells. Transl Res. 148:171–179. 2006. View Article : Google Scholar : PubMed/NCBI
13	Lee HS and Song CY: Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am J Nephrol. 29:62–70. 2009. View Article : Google Scholar : PubMed/NCBI
14	Turer AT and Scherer PE: Adiponectin: Mechanistic insights and clinical implications. Diabetologia. 55:2319–2326. 2012. View Article : Google Scholar : PubMed/NCBI
15	Chen Z, Li S, Zhao W, Chen X and Wang X: Protective effect of co-administration of rosuvastatin and probucol on atherosclerosis in rats. Can J Physiol Pharmacol. 92:797–803. 2014. View Article : Google Scholar : PubMed/NCBI
16	Hulthe J and Fagerberg B: Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 22:1162–1167. 2002. View Article : Google Scholar : PubMed/NCBI
17	Fan X, Wang J, Hou J, Lin C, Bensoussan A, Chang D, Liu J and Wang B: Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway. J Transl Med. 13:922015. View Article : Google Scholar : PubMed/NCBI
18	Yao S, Zong C, Zhang Y, Sang H, Yang M, Jiao P, Fang Y, Yang N, Song G and Qin S: Activating transcription factor 6 mediates oxidized LDL-induced cholesterol accumulation and apoptosis in macrophages by up-regulating CHOP expression. J Atheroscler Thromb. 20:94–107. 2013. View Article : Google Scholar : PubMed/NCBI
19	Xiong G, Li L, Sun S, Li T, Liao D, Shu C and Tuo Q: Subcellular localization of DAXX influence ox-LDL induced apoptosis in macrophages. Mol Biol Rep. 41:7183–7190. 2014. View Article : Google Scholar : PubMed/NCBI
20	Samarakoon R, Overstreet JM and Higgins PJ: TGF-β signaling in tissue fibrosis: Redox controls, target genes and therapeutic opportunities. Cell Signal. 25:264–268. 2013. View Article : Google Scholar : PubMed/NCBI
21	Samarakoon R, Overstreet JM, Higgins SP and Higgins PJ: TGF-β1→SMAD/p53/USF2→PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res. 347:117–128. 2012. View Article : Google Scholar : PubMed/NCBI
22	Antus B, Harnasi G, Drozdovszky O and Barta I: Monitoring oxidative stress during chronic obstructive pulmonary disease exacerbations using malondialdehyde. Respirology. 19:74–79. 2014. View Article : Google Scholar : PubMed/NCBI
23	Youseff BH, Holbrook ED, Smolnycki KA and Rappleye CA: Extracellular superoxide dismutase protects Histoplasma yeast cells from host-derived oxidative stress. PLoS Pathog. 8:e10027132012. View Article : Google Scholar : PubMed/NCBI
24	Resch U, Tatzber F, Budinsky A and Sinzinger H: Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol. 61:262–274. 2006. View Article : Google Scholar : PubMed/NCBI